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ABSTRACT 
Trasdermal drug delivery system is topically administered medicaments in the form of patches that deliver drugs for systemic effects at a predetermined and 
controlled rate. Today about 74% of drugs are taken orally and are found not to be as effective as desired. To improve such characters transdermal drug 
delivery system was emerged. Drug delivery through the skin to achieve a systemic effect of a drug is commonly known as transdermal drug delivery and 
differs  from  traditional  topical  drug  delivery.      This  review  article  is  written  to  provide  a  coverage  commentary  of  the  recent  advancements  in  TDD 
enhancement techniques. Skin penetration enhancement techniques have been developed to improve bioavailability and increase the range of drugs for which 
topical and transdermal delivery is a viable option. The present review article explores the overall study on transdermal drug delivery system (TDDS) which 
leads to novel drug delivery system (NDDS). 
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INTRODUCTION:  
Transdermal  drug  delivery  systems  (TDDS)  are  defined  as 
self contained, discrete dosage forms which, when applied to 
intact  skin,  deliver  the  drug(s),  through  the  skin,  at  a 
controlled  rate  to  systemic  circulation
1-3.  TDDS  in 
comparison  to  conventional  pharmaceutical  dosage  forms, 
offer  many  advantages,  such  as  reduced  side  effects, 
improved  patient  compliance,  elimination  of  first-pass 
metabolism,  and  sustained  drug  delivery
4-6.  Cardiovascular 
diseases  account  for  a  large  proportion  of  all  deaths  and 
disability worldwide. At present, the most common form of 
delivery of drugs is the oral route. While this has the notable 
advantage  of  easy  administration,  it  also  has  significant 
drawbacks  namely  poor  bioavailability  due  to  hepatic 
metabolism  (first  pass)  and  the  tendency  to  produce  rapid 
blood level spikes (both high and low), leading to a need for 
high  and/or  frequent  dosing,  which  can  be  both  cost 
prohibitive and inconvenient
7. 
PERMEATION ENHANCERS: 
Three pathways are suggested for drug penetration through 
the  skin:  polar,  non-polar,  and  polar/non-polar.  The 
enhancers act by altering one of these pathways. The key to 
altering the polar pathway is to cause protein conformational 
change or solvent swelling. The key to altering the nonpolar 
pathway  is  to  alter  the  rigidity  of  the  lipid  structure  and 
fluidize the crystalline pathway (this substantially increases 
diffusion). The fatty acid enhancers increase the fluidity of 
the lipid portion of the Stratum Corneum. Some enhancers 
(binary vehicles) act on both polar and nonpolar pathways by 
altering the multilaminate pathway for penetrants. Enhancers 
can  increase  the  drug  diffusivity  in  the  Stratum  Corneum 
(SC)  by  dissolving  the  skin  lipids  or  by  denaturing  skin 
proteins. The  type  of  enhancer  employed  has  a  significant 
impact on the design and development of the product. The 
success of dermatological drug products that are intended for 
systemic drug delivery, such as the transdermal, depends on 
the  ability  of  the  drug  to  penetrate  through  the  skin  in 
sufficient quantities to achieve its desired therapeutic effect. 
The methods employed for modifying the barrier properties 
of the SC to enhance the drug penetration (and absorption) 
through the skin can be categorized as (1) Chemical and (2) 
physical methods of enhancement
8. 
 
CHEMICAL ENHANCERS 
Chemicals that promote the penetration of topically applied 
drugs  are  commonly  referred  to  as  accelerants,  absorption 
promoters, or penetration enhancers. Chemical enhancers act 
by 
1.  Increasing  the  drug  permeability  through  the  skin  by 
causing reversible damage to the SC.  
2.  Increasing  (and  optimizing)  thermodynamic  activity  of 
the drug when functioning as co solvent. 
3.   Increasing the partition coefficient of the drug to promote 
its release from the vehicle into the skin.  
4.  Conditioning the SC to promote drug diffusion.  
5.  Promoting penetration and establish drug reservoir in the 
SC. 
PHYSICAL ENHANCERS 
The  iontophoresis  and  ultra  sound  (also  known  as 
phonophoresis or sonophoresis) techniques are examples of 
physical  means  of  enhancement  that  have  been  used  for 
enhancing  percutaneous  penetration  (and  absorption)  of 
various therapeutic agents
9.   
ROUTES  FOR  DRUG  PENETRATION  THROUGH 
SKIN –  
There  are  two  major  routes  named  as  Macro  (Fig.  1)  and 
Micro(Fig. 2) routes.  
FACTORS AFFCETING DRUG PENETRATION  
The  physicochemical  nature  of  the  drug  particularly  size, 
solubility and partition coefficient  
1.The timescale of observation  
2.The site and condition of the skin  
3.The formulation  
4.How vehicle components temporarily change the properties 
of the stratum corneum  
CLASSIFICATION OF TDDS  
1.  Matrix  System:  Drug  in  Adhesive  System  (Adhesive 
Diffusion Controlled TDDS) (fig.3) 
The drug reservoir is formed by dispersing the drug in an 
adhesive polymer and then spreading the medicated polymer 
adhesive by solvent casting or by melting the adhesive (in 
case of hot-melt adhesives) onto an impervious backing layer.  
The drug reservoir layer is then covered by a non-medicated 
rate  controlling  adhesive  polymer  of  constant  thickness  to 
produce  an  adhesive  diffusion  controlling  drug  delivery 
system.  Vishwakarma Sanjay kumar et al. IRJP 2012, 3 (8) 
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Deponit®  (Nitroglycerine)  for  once  a  day  medication  of 
angina pectoris 
2.  Matrix  System:  Matrix  Dispersion  System  (Matrix 
Diffusion Controlled System)
10, 11, 12 (Fig. 4) 
The  drug  is  dispersed  homogeneously  in  a  hydrophilic  or 
lipophilic polymer matrix.  
This  drug  containing  polymer  disk  then  is  fixed  onto  an 
occlusive base plate in a compartment fabricated from a drug-
impermeable backing layer.  
Instead  of  applying  the  adhesive  on  the  face  of  the  drug 
reservoir, it is spread along the circumference to form a strip 
of adhesive rim.  
Nitro Dur® (Nitroglycerine) used for once a day medication 
of angina pectoris
10-12 
3. Reservoir System (Membrane Moderated TDDS): (Fig. 
5) 
In this system, the drug reservoir is embedded between an 
impervious backing layer and a rate controlling membrane. 
The  drug  releases  only  through  the  rate  controlling 
membrane, which can be microporous or non-porous. In the 
drug reservoir compartment, the drug can be in the form of a 
solution,  suspension,  or  gel  or  dispersed  in  solid  polymer 
matrix. On the outer surface of the polymeric membrane a 
thin  layer  of  drug-compatible,  hypoallergenic  adhesive 
polymer can be applied. The rate of drug release from this 
type of transdermal drug delivery system can be tailored by 
varying  the  polymer  composition,  permeability  coefficient 
and thickness of the rate controlling membrane. 
TransdermScop®  (Scopolamine)  for  3  days  protection  of 
motion  sickness  and  TransdermNitro®  (Nitroglycerine)  for 
once a day medication of angina pectoris
10-12.  
This drug delivery system is a combination of reservoir and 
matrix-dispersion systems. The drug reservoir is formed by 
first  suspending the  drug  in  an  aqueous  solution  of  water-
soluble  polymer  and  then  dispersing  the  solution 
homogeneously in a lipophilic polymer to form thousands of 
unleachable,  microscopic  spheres  of  drug  reservoirs.  The 
thermodynamically unstable dispersion is stabilized quickly 
by  immediately  cross-linking  the  polymer  in  situ.  A 
transdermal  system  therapeutic  system  thus  formed  as  a 
medicated disc positioned at the centre and surrounded by an 
adhesive rim. Nitro-dur® System (Nitroglycerin) for once a 
day treatment of angina pectoris. 
TYPES OF TRANSDERMAL PATCHES 
Four Major Transdermal Systems 
1. Single Layer Drug In Adhesive 
The  Single-layer  Drug-in-Adhesive  system  is  characterized 
by  the  inclusion  of  the  drug  directly  within  the  skin 
contacting adhesive. In this transdermal system design, the 
adhesive not only serves to affix the system to the skin, but 
also serves as the formulation foundation, containing the drug 
and all the excipients under a single backing film9. The rate 
of release of drug from this type of system is dependent on 
the diffusion across the skin. The intrinsic rate of drug release 
from this type of drug delivery system is defined by 
 
 
 
Where, 
Cr is the drug concentration in the reservoir compartment and 
Pa and Pm are the permeability coefficients of the adhesive 
layer and the rate controlling membrane, Pm is the sum of 
permeability  coefficients  simultaneous  penetrations  across 
the  pores  and  the  polymeric  material.  Pm  and  Pa, 
respectively, are defined as follows. 
   
 
 
 
 
 
where Km/r and Ka/m are the partition coefficients for the 
interfacial  partitioning  of  drug  from  the  reservoir  to  the 
membrane and from the membrane to adhesive respectively; 
Dm  and  Da  are  the  diffusion  coefficients  in  the  rate 
controlling membrane and adhesive layer, respectively; and 
hm  and  ha  are  the  thicknesses  of  the  rate  controlling 
membrane and adhesive layer, respectively
13. 
2. Multilayer Drug In Adhesive 
The Multi-layer Drug-in-Adhesive is similar to the Single-
layer  Drug-in-Adhesive  in  that  the  drug  is  incorporated 
directly  into  the  adhesive.  However,  the  multi-layer 
encompasses either the addition of a membrane between two 
distinct  drug-in-adhesive  layers  or  the  addition  of  multiple 
drug-in-adhesive layers under a single backing film. 
The rate of drug release in this system is defined by: 
 
 
 
Where  
Ka/r is the partition coefficient for the interfacial partitioning 
of the drug from the reservoir layer to adhesive layer. 
3.Drug Resrvoir In Adhesive 
The Reservoir transdermal system design is characterized by 
the  inclusion  of  a  liquid  compartment  containing  a  drug 
solution or suspension separated from the release liner by a 
semi-permeable  membrane  and  adhesive.  The  adhesive 
component of the product responsible for skin adhesion can 
either  be  incorporated  as  a  continuous  layer  between  the 
membrane  and  the  release  liner  or  in  a  concentric 
configuration around the membrane. 
The  rate  of  drug  release  from  this  drug  reservoir  gradient 
controlled system is given by: 
 
 
) 
In the above equation, the thickness of the adhesive layer for 
drug molecules to diffuse through increases with time ha (t). 
To  compensate  for  this  time  dependent  increase  in  the 
diffusional path due to the depletion of drug dose by release, 
the drug loading level is also increased with the thickness of 
diffusion path A (ha). 
4. Drug Matrix In Adhesive 
The Matrix system design is characterized by the inclusion of 
a semisolid matrix containing a drug solution or suspension 
which  is  in  direct  contact  with  the  release  liner.  The 
component responsible for skin adhesion is incorporated in 
an overlay and forms a concentric configuration around the 
semisolid matrix, Where A is the initial drug loading dose 
dispersed  in  the  polymer  matrix  and  Cp  and  Dp  are  the 
solubility  and  diffusivity  of  the  drug  in  the  polymer 
respectively.  Since,  only  the  drug  species  dissolved  in  the 
polymer can release, Cp is essentially equal to CR, where CR 
is the drug concentration in the reservoir compartment. Vishwakarma Sanjay kumar et al. IRJP 2012, 3 (8) 
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BASIC COMPONENT OF TDDS:  
1.  Polymer matrix / Drug reservoir. 
2.  Selection of drug 
3.  Permeation enhancers. 
4.  Pressure sensitive adhesive (PSA). 
5.  Backing laminates. 
6.  Release liner 
7.  Other excipients like plasticizers and solvent 
1. POLYMER MATRIX/DRUG RESERVOIR SYSTEM 
Polymers are the heart of TDDS, which control the release of 
the drug from the device. Polymer matrix can be prepared by 
dispersion of drug in liquid or solid state synthetic polymer 
base. Polymers used in TDDS should have good stability and 
compatibility  with  the  drug  and  other  components  of  the 
system and they should provide effective released of a drug 
throughout the device with safe status.  
THE  POLYMER  USED  FOR  TDDS  CAN  BE 
CLASSIFIED AS:  
Natural Polymer: e.g. cellulose derivatives, zein, gelatine, 
shellac, waxes, gums, natural rubber and chitosan etc.  
Synthetic  Elastomers:  e.g.  polybutadiene,  hydrin  rubber, 
polyisobutylene,  silicon  rubber,  nitrile,  acrylonitrile, 
neoprene, butylrubber etc.  
Synthetic Polymer: e.g. polyvinylalcohol, polyvinylchloride, 
polyethylene,  polypropylene,  polyacrylate,  polyamide, 
polyurea, polyvinylpyrrolidone, polymethylmethacrylate etc. 
The  polymer  like  polyethylene  glycol,  eudragits  , 
ethylcellulose,  polyvinylpyrrolidone  and  hydroxy- 
propylmethylcellulose  are used as matrix type TDDS. The 
polymers  like  EVA  ,  silicon rubber  and  polyurethane    are 
used as rate controlling TDDS
14-19. 
2.  SELECTION  OF  DRUGS:  The  selection  of  drug  for 
TDDS  is  based  on  physicochemical  properties  of  drug. 
Transdermal drug delivery system is much suitable for drug 
having 
20, 21.  
1.  Extensive first pass metabolism. 
2.  Narrow therapeutic window.  
3.  Short  half-life  which  causes  non-compliance  due  to 
frequent dosing. 
4.   Dose should be less (mg/day) 
22. 
5.   Low molecular weight (less than 500 Daltons). 
6.   Adequate solubility in oil and water (log P in the range of 
1-3). 
7.   Low melting point (less than 200°C).  
3. PERMEATION ENHANCERS:  
These  compounds  are  useful  to  increase  permeability  of 
stratum corneum by interacting with structural components of 
stratum  corneum  i.e.,  proteins  or  lipids  to  attain  higher 
therapeutic levels of the drug 
23. They alter the protein and 
lipid  packaging  of  stratum  corneum,  thus  chemically 
modifying  the  barrier  functions  leading  to  increased 
permeability 
24.  Some  example  are  Dimethyl  sulfoxide, 
Propylene  glycol,2-Pyrrolidone,  Isopropyl  myristate, 
Laurocapram  (Azone),  Sodium  lauryl  sulfate,  Sorbitan 
monolaurate, Pluronic, Cardamom oil, Caraway oil, Lemon 
oil, Menthol, dlimonene, Linoleic acid 
25.  
4. PRESSURE SENSITIVE ADHESIVE: 
The  pressure-sensitive  adhesive  (PSA)  affixes  the 
transdermal drug delivery system firmly to the skin. It should 
adhere with not more than applied finger pressure,  
be  aggressively  and  permanently  tachy  and  exert  a  strong 
holding force. Additionally, it should be removable from the 
smooth surface without leaving a residue . Adhesives must be 
skin-compatible, causing minimal irritation or sensitization, 
and removable without inflicting physical trauma or leaving 
residue. In addition, they must be able to dissolve drug and 
excipient  in  quantities  sufficient  for  the  desired 
pharmacological  effect  without  losing  their  adhesive 
properties and skin tolerability.  
PSAs  used  in  commercially  available  transdermal  systems 
include  polyacrylate,  polyisobutylene  and  polysiloxane 
28. 
Polyacrylates  are  most  widely  used.  In  general, all acrylic 
adhesives  are  polar  in  character,  allowing  them  to  absorb 
moisture readily and to maintain adhesion to wet skin. They 
also dissolve most drugs well, enabling high drug loading of 
polyacrylate  matrices.  Polyisobutylenes  (PIBs),  in  contrast, 
are characterized by a low solvent capacity for drugs. PIBs 
are  often  used  in  membrane-controlled  systems  where  the 
initial burst of drug released from the adhesive layer should 
be limited. PIB-based adhesives are mixtures of high and low 
molecular  weight  polymers,  which  provide  cohesion  and 
tackiness, respectively. By adjusting the composition of the 
PIB  formulation,  cold  flow  and  adhesiveness  can  be 
customized for each system.  
Silicone,  adhesives  are  characterized  by  low  allergenicity. 
Similar  to  PIBs,  silicones  dissolve  most  drugs  poorly  and 
regulate  tackiness  and  cohesion  through  polymer  size. 
Molecular  weight  of  silicones,  however,  can  be  hard  to 
control during storage of drug-adhesive formulations, since 
drugs  containing  amine  groups  can  catalyze  further 
polymerization in silicone adhesives retaining residual silanol 
groups. To address this problem, special silicones have been 
developed  that  are  rendered  resistant  to  amine-catalyzed 
condensation  through  end-capping  of  silanol  functional 
groups.  Hot  Melt  Pressure  Sensitive  Adhesives  (HMPSA), 
HMPSA melt to a viscosity suitable for coating, but when 
they are cooled they generally stay in a flowless state. They 
are thermoplastic in nature.  
5. BACKING LAMINATE:  
Backing  materials  must  be  flexible  while  possessing  good 
tensile strength. Commonly used materials are polyolefin’s, 
polyesters, and elastomers in clear, pigmented, or metallized 
form. Elastomeric materials such as low-density polyethylene 
conform more readily to skin movement and provide better 
adhesion  than  less  compliant  materials  such  as  polyester. 
Backing  materials  should  also  have  low  water  vapour 
transmission rates to promote increased skin hydration and, 
thus, greater skin permeability. In systems containing drug 
within a  liquid  or  gel,  the  backing  material  must  be  heat-
sealable to allow fluid-tight packaging of the drug reservoir 
using  a  process  known  as  form-fill-seal.  The  most 
comfortable  backing  will  be  the  one  that  exhibits  lowest 
modulus or high flexibility, good oxygen transmission and a 
high moisture vapour transmission rate 
29.  
are Ethylene vinyl acetate copolymers, Paraffin waxes, Low 
density  polypropylene,  Styrene-butadiene  copolymers,  and 
Ethylene-ethacrylate  copolymers.  Uncompounded  HMPSA 
are Polyesters, Polyamides and Polyurethanes. 
Examples  of  some  backing  materials  are  vinyl,  polyester 
films,  Polyester-polypropylene  films,  Polypropylene  resin, 
Polyethylene  resin,  Polyurethylene,  Co  Tran  9722  film, 
Ethylene-vinyl acetate, Aluminized plastic laminate. 
6. RELEASE LINERS: 
 During storage the patch is covered by a protective liner that 
is  removed  and  discharged  immediately  before  the 
application of the patch to skin. It is therefore regarded as a 
part of the primary packaging material rather than a part of 
dosage form for delivering the drug.  
However, as the liner is in intimate contact with the delivery 
system,  it  should  comply  with  specific  requirements Vishwakarma Sanjay kumar et al. IRJP 2012, 3 (8) 
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regarding  chemical  inertness  and  permeation  to  the  drug, 
penetration  enhancer  and  water.  Typically,  release  liner  is 
composed of a base layer which may be non-occlusive (e.g. 
paper  fabric)  or  occlusive  (e.g.  polyethylene, 
polyvinylchloride)  and  a  release  coating  layer  made  up  of 
silicon or teflon. 
Other materials used for TDDS release liner include polyester 
foil and metalised laminates 
30.  
7. OTHER EXCIPIENTS: 
 Various  solvents  such  as  chloroform,  methanol,  acetone, 
isopropanol  and  dichloromethane  are  used  to  prepare  drug 
reservoir.  In  addition  plasticizers  such  as  dibutyl  pthalate, 
triethyl citrate, polyethylene glycol and propylene glycol are 
added to provide plasticity to the transdermal patch 
31.  
ADVANTAGES
31 
1.  Transdermal  medication  delivers a  steady  infusion  of  a 
drug over an extended period of time. Adverse effects or 
therapeutic failure frequently associated with intermittent 
dosing can also be avoided. 
2.  Transdermal delivery can increase the therapeutic value 
of many drugs by avoiding specific problems associated 
with  the  drug  e.g.,  gastro-intestinal  irritation,  low 
absorption,  decomposition  due  to  hepatic  "first-pass" 
effect,  formation  of  metabolites  that  cause  side  effects, 
short half-life necessitating frequent dosing etc. 
3.  Due  to  the  above  advantage,  it  is  possible  that  an 
equivalent  therapeutic  effect  can  be  elicited  via 
transdermal drug input with a lower daily dose of the drug 
than is necessary, if, for example, the drug is given orally. 
4.  The  simplified  medication  regimen  leads  to  improved 
patient  compliance  and  reduced  inter  and  intra-patient 
variability. 
5.  At  times  the  maintenance  desired.  Application  and 
removal of transdemal patche produce the optimal effect 
of pharmacological effect. 
6.  Self-administration is possible with these systems. 
7.  Drug  input  can  be  terminated  at  any  point  of  time  by 
removing transdermal patch. 
DISADVANTAGES
31 
1.   Drug dose is large. 
2.   Drug  has  larger  molecular  size  (makes  absorption 
difficult; should be ideally be  below 800-1000daltons) 
3.   Drug is sensitising and irritating. 
4.   Drug is metabolised in skin. 
5.   Drug undergoes protein binding in skin. 
6.   Drug  is  highly  lipophilic  or  hydrophilic  (should  be 
moderately soluble in both oil and water)  
APPLICATIONS OF TRANSDERMAL PATCHES  
1.  The highest selling transdermal patch in the United States 
is the nicotine patch, which releases nicotine in controlled 
doses to help with cessation of tobacco smoking. 
2.  Two opioid medications used to provide round-the-clock 
relief for severe pain are often prescribed in patch form: 
Fentanyl  (marketed  as  Duragesic)  and  Buprenorphine 
(marketed as BuTrans).  
3.  Estrogen  patches  are  sometimes  prescribed  to  treat 
menopausal  symptoms  as  well  as  post-menopausal 
osteoporosis.  Other  transdermal  patches  for  hormone 
delivery  include  the  contraceptive  patch  (marketed  as 
Ortho Evra or Evra).  
4.  Nitroglycerin  patches  are  sometimes  prescribed  for  the 
treatment of angina in lieu of sublingual pills. 
5.   The  anti-hypertensive  drug  Clonidine  is  available  in 
transdermal patch form. 
6.   Transdermal form of the MAOI selegiline, became the 
first transdermal delivery agent for an antidepressant. 
7.   Transdermal  delivery  agent  for  the  Attention  Deficit 
Hyperactivity Disorder (ADHD). 
THE FUTURE SCOPE OF TRANSDERMAL PATCHES  
1.   An insulin patch 
2.   Sufentanil patch for chronic cancer pain 
3.   Varenicline patch for smoking cessation 
4.   Estrogen  and  testosterone  patches  for  post-menopausal 
women 
5.   Selegiline patch for depression in the elderly and cocaine 
addiction 
6.   Clonidine  transdermal  for  the treatment  of  delerium in 
trauma patients 
7.   Dexamethasone iontophoretic delivery for the treatment 
of tennis elbow 
8.  An  iontophoretic  sumatriptan  patch  for  migraine 
treatment, and 
9.  Transdermal glyceryl trinitrate for acute stroke therapy, to 
name a few  
CONCLUSION 
Transdermal drug delivery system is useful for topical and 
local action of the drug. The drug which shows hepatic first 
pass  effect  and  unstable  in  GI  conditions,  are  suitable 
candidate  for  TDDS.  Due  to  the  recent  advances  in 
technology and the incorporation of the drug to the site of 
action  without  rupturing  the  skin  membrane  transdermal 
route  is  becoming the  most  widely  accepted  route  of  drug 
administration and many new researches are going on in the 
present day to incorporate newer drugs via the system. The 
properties of the drug, the characteristics of the transdermal 
device, selection of in-vivo model and the status of patient’s 
skin are all important for safe and effective drug delivery. 
The transdermal drug delivery system could be one day one 
of the best novel drug delivery system. 
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FIGURE 1: DRUG PERMEATION THROUGH THE SKIN 
 
 
 
FIGURE 2: MECHANISAM OF SKIN PERMEATION 
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FIGURE 4: MATRIX DISPERSION SYSTEM 
 
FIGURE 5: RESERVOIR TRANSDERMAL PATCH 
 
FIGURE 6: MICRORESERVOIR SYSTEM 
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